A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?
المؤلفون المشاركون
Çelik, Sebahattin
Erten, Remzi
Batur, Abdulsamed
Suvak, Burak
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-4، 4ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-08-06
دولة النشر
مصر
عدد الصفحات
4
التخصصات الرئيسية
الملخص EN
Background.
Since neoadjuvant treatment in esophageal cancer began to become popular, a complete pathological response at the primary tumour site has been commonly reported.
An issue of conflict is whether complete response in the esophageal lumen means that the esophagus is completely tumour-free.
Another important issue is whether lymph nodes that are retrieved from pathologically complete response cases are also tumour-free or not.
There is a gap in the esophageal cancer staging system for ypT0 N2 M0 tumours that have received neoadjuvant therapy.
Here, we will discuss the problem about staging of esophageal cancer associated with neoadjuvant therapy.
Case.
A female aged 40 years complaining of dysphagia was diagnosed as having locally advanced thoracic esophageal cancer.
Neoadjuvant therapy decision was taken by oncology committee.
Six weeks after neoadjuvant therapy, with a curative intention, minimal invasive surgery was performed.
The pathology report was as follows.
“There were no neoplastic cells in the suspected area of the esophageal mucosa upon examination with all staining.
There was no cancer at resection margins.
Four metastatic lymph nodes were infiltrated with squamous cell cancer.” Conclusion.
Despite the growing use of neoadjuvant treatment in locally advanced esophageal cancer in world, we do not have a protocol for the evaluation of these patients’ pathology reports.
We believe that new studies and new ideas are needed to resolve this dilemma associated with neoadjuvant therapy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Çelik, Sebahattin& Erten, Remzi& Batur, Abdulsamed& Suvak, Burak. 2015. A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?. Case Reports in Pathology،Vol. 2015, no. 2015, pp.1-4.
https://search.emarefa.net/detail/BIM-1059692
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Çelik, Sebahattin…[et al.]. A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?. Case Reports in Pathology No. 2015 (2015), pp.1-4.
https://search.emarefa.net/detail/BIM-1059692
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Çelik, Sebahattin& Erten, Remzi& Batur, Abdulsamed& Suvak, Burak. A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?. Case Reports in Pathology. 2015. Vol. 2015, no. 2015, pp.1-4.
https://search.emarefa.net/detail/BIM-1059692
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1059692
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر